Novo NordiskNVO
Market Cap: $584B
About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees: 69,260
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
85% more first-time investments, than exits
New positions opened: 204 | Existing positions closed: 110
30% more repeat investments, than reductions
Existing positions increased: 744 | Existing positions reduced: 573
10% more funds holding in top 10
Funds holding in top 10: 78 [Q1] → 86 (+8) [Q2]
10% more capital invested
Capital invested by funds: $43.2B [Q1] → $47.6B (+$4.39B) [Q2]
5% more funds holding
Funds holding: 1,714 [Q1] → 1,808 (+94) [Q2]
0.07% more ownership
Funds ownership: 9.79% [Q1] → 9.85% (+0.07%) [Q2]
4% less call options, than puts
Call options by funds: $1.09B | Put options by funds: $1.13B
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Cantor Fitzgerald Louise Chen 70% 1-year accuracy 112 / 159 met price target | 22%upside $160 | Overweight Reiterated | 19 Aug 2024 |
BMO Capital Evan David Seigerman 71% 1-year accuracy 10 / 14 met price target | 22%upside $160 | Outperform Maintained | 8 Aug 2024 |
Cantor Fitzgerald Louise Chen 70% 1-year accuracy 112 / 159 met price target | 22%upside $160 | Overweight Reiterated | 5 Aug 2024 |
Cantor Fitzgerald Louise Chen 70% 1-year accuracy 112 / 159 met price target | 22%upside $160 | Overweight Reiterated | 1 Jul 2024 |
BMO Capital Evan David Seigerman 71% 1-year accuracy 10 / 14 met price target | 24%upside $163 | Outperform Maintained | 25 Jun 2024 |
Financial journalist opinion
Based on 48 articles about NVO published over the past 30 days